BioCentury
ARTICLE | Company News

Athenex grants Almirall rights to KX2-391

December 15, 2017 9:46 PM UTC

Athenex Inc. (NASDAQ:ATNX) granted Almirall S.A. (Madrid:ALM) exclusive rights to develop and commercialize KX2-391 (KX-01) in the U.S. and parts of Europe, including Russia. Athenex will receive $55 million up front and is eligible for up to $220 million in milestones, plus tiered royalties starting at 15%.

Athenex is responsible for all preclinical and clinical studies in the U.S...

BCIQ Company Profiles

Almirall S.A.

Athenex Inc.

BCIQ Target Profiles

Src

Tubulin polymerase